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Ibrutinib Regimens versus Chemoimmunotherapy
in Older Patients with Untreated CLL
J.A. Woyach, A.S. Ruppert, N.A. Heerema, W. Zhao, A.M. Booth, W. Ding,
N.L. Bartlett, D.M. Brander, P.M. Barr, K.A. Rogers, S.A. Parikh, S. Coutre,
A. Hurria,* J.R. Brown, G. Lozanski, J.S. Blachly, H.G. Ozer, B. Major‑Elechi,
B. Fruth, S. Nattam, R.A. Larson, H. Erba, M. Litzow, C. Owen, C. Kuzma,
J.S. Abramson, R.F. Little, S.E. Smith, R.M. Stone, S.J. Mandrekar, and J.C. Byrd

A BS T R AC T
BACKGROUND

Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but
has not been compared with chemoimmunotherapy. We conducted a phase 3 trial
to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab,
relative to chemoimmunotherapy.
METHODS

Patients 65 years of age or older who had untreated CLL were randomly assigned
to receive bendamustine plus rituximab, ibrutinib, or ibrutinib plus rituximab. The
primary end point was progression-free survival. The Alliance Data and Safety Monitoring Board made the decision to release the data after the protocol-specified efficacy threshold had been met.
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RESULTS

A total of 183 patients were assigned to receive bendamustine plus rituximab, 182
to receive ibrutinib, and 182 to receive ibrutinib plus rituximab. Median progressionfree survival was reached only with bendamustine plus rituximab. The estimated
percentage of patients with progression-free survival at 2 years was 74% with bendamustine plus rituximab and was higher with ibrutinib alone (87%; hazard ratio for
disease progression or death, 0.39; 95% confidence interval [CI], 0.26 to 0.58;
P<0.001) and with ibrutinib plus rituximab (88%; hazard ratio, 0.38; 95% CI, 0.25
to 0.59; P<0.001). There was no significant difference between the ibrutinib-plusrituximab group and the ibrutinib group with regard to progression-free survival
(hazard ratio, 1.00; 95% CI, 0.62 to 1.62; P = 0.49). With a median follow-up of 38
months, there was no significant difference among the three treatment groups with
regard to overall survival. The rate of grade 3, 4, or 5 hematologic adverse events
was higher with bendamustine plus rituximab (61%) than with ibrutinib or ibrutinib
plus rituximab (41% and 39%, respectively), whereas the rate of grade 3, 4, or 5 nonhematologic adverse events was lower with bendamustine plus rituximab (63%) than
with the ibrutinib-containing regimens (74% with each regimen).
CONCLUSIONS

Among older patients with untreated CLL, treatment with ibrutinib was superior to
treatment with bendamustine plus rituximab with regard to progression-free survival. There was no significant difference between ibrutinib and ibrutinib plus rituximab with regard to progression-free survival. (Funded by the National Cancer Institute and Pharmacyclics; ClinicalTrials.gov number, NCT01886872.)
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hronic lymphocytic leukemia (CLL)
is the most prevalent form of leukemia in
adults and is incurable in most cases. Investigation into the pathogenesis of CLL has
implicated B-cell receptor signaling as a central
driver, and targeting of this pathway through inhibition of Bruton’s tyrosine kinase (BTK) has delayed and prevented the onset of disease in experimental systems.1,2
Among patients 65 years of age or older, chemo
immunotherapy with either chlorambucil plus
obinutuzumab3 or bendamustine plus rituximab4
has shown efficacy and represents standard treatment, although the approach is often modified.
Chemoimmunotherapy is associated with toxic effects in many patients, and the risk of toxic effects
increases with age. Thus, a targeted oral therapy
that is effective and is associated with an acceptable toxic-effect profile could be of value in patients with CLL.
Ibrutinib is an irreversible BTK inhibitor
that abrogates CLL-related cell signaling, adhesion, proliferation, and homing in vitro and in
vivo.5-11 Among patients with CLL, treatment with
single-agent ibrutinib led to a median progression-free survival of 52 months among those
who had relapsed or refractory disease12; among
those who received ibrutinib as initial treatment,
the percentage of patients who were alive and
free from disease progression at 2 years was
89%.13 Ibrutinib has been widely used as an initial treatment for CLL since 2016, when it was
approved by the Food and Drug Administration
and by the European Medicines Agency for this
indication, on the basis of its superiority to
chlorambucil.14 The benefit of ibrutinib relative
to standard chemoimmunotherapy remains a critical consideration.
The addition of rituximab or other CD20
antibodies to chemotherapy prolongs progression-free survival and overall survival,3,15 and such
antibodies have been thought to be indispensable in the treatment of CLL. Whether the addition of rituximab to ibrutinib leads to increased
efficacy is controversial. In this phase 3 trial
(A041202), we address two main questions. First,
among older patients with untreated CLL, is treatment with ibrutinib or ibrutinib plus rituximab
superior to treatment with bendamustine plus
rituximab? Second, does the addition of rituximab to single-agent ibrutinib lead to increased
efficacy?
2518
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Me thods
Patients

Eligible patients were 65 years of age or older
and had untreated CLL for which treatment was
indicated, as defined by International Workshop
on CLL (IWCLL) criteria.16 The IWCLL criteria and
a full list of eligibility criteria are provided in the
Supplementary Appendix, available with the full
text of this article at NEJM.org.
Trial Oversight

This phase 3 trial was coordinated by the Alliance
for Clinical Trials in Oncology (Alliance) in collaboration with the National Cancer Institute Cancer Trials Support Unit and was approved by a
central institutional review board, as well as local
institutional review boards as required by participating institutions. The trial was conducted in
accordance with the principles of the Declaration
of Helsinki. The data were collected by the investigators and entered into an electronic database
that was maintained by the Alliance Statistics and
Data Center. To ensure data quality, a review of
data was performed by the Alliance Statistics and
Data Center and by the trial chairperson in accordance with Alliance policies. The trial was
monitored at least twice annually by the Alliance
Data and Safety Monitoring Board, a standing
committee that was composed of persons from
inside and outside the Alliance. All the authors
reviewed and approved the manuscript and vouch
for the completeness and accuracy of the data and
the fidelity of the trial to the protocol, available at
NEJM.org. No one who is not an author contributed to authorship of the manuscript. The National Cancer Institute was the trial sponsor and
obtained ibrutinib under a cooperative research
and development agreement with Pharmacyclics
(a subsidiary of AbbVie). Pharmacyclics had no role
in the design of the trial, collection or interpretation of the data, or authorship of the manuscript.
Fluorescence in situ hybridization (FISH) probes
were provided by Abbott Molecular and Leica Biosystems.
Evaluation, Randomization, and Treatment

Before each patient underwent randomization, a
blood sample was submitted for central testing for
methylation at the promoter region of the ZAP70
gene (encoding zeta chain–associated protein kinase 70 [ZAP70]).17 Unmethylated ZAP70 correlates
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with expression of ZAP70, a finding that conveys
a poor prognosis. Approximately 76% of CLL cells
that express ZAP70 also contain unmutated IgVH
(immunoglobulin variable heavy chain) genes,
another predictor of poor prognosis. Sequencing
of IgVH genes in CLL cells was not routinely performed in this trial. The following risk factors for
CLL were used for stratification: ZAP70 methylation status on central testing (unmethylated [<20%]
vs. methylated [≥20%]), risk category according to
modified Rai stage (intermediate vs. high),18 and
status with regard to del(17p13.1) or del(11q22.3)
on local FISH analysis (absent vs. present).
Patients were randomly assigned, in a 1:1:1
ratio, to receive bendamustine plus rituximab,
ibrutinib, or ibrutinib plus rituximab. A dynamic
randomization method was used, with stratification according to risk factors for CLL.19 Treatment was administered in 28-day cycles. Bendamustine-plus-rituximab therapy consisted of six
cycles of bendamustine (administered at a dose of
90 mg per square meter of body-surface area on
days 1 and 2 of each cycle) plus rituximab (administered at a dose of 375 mg per square meter on
the day before day 1 of cycle 1 and then at a dose
of 500 mg per square meter on day 1 of cycles 2
through 6). At the investigator’s discretion, the
cycle 1 dose of bendamustine could be 70 mg per
square meter. Ibrutinib was administered at a dose
of 420 mg daily until the patient had unacceptable
toxic effects or disease progression. Ibrutinib-plusrituximab therapy consisted of ibrutinib (administered as described previously and given before
rituximab on days when they were administered
together) plus rituximab (administered at a dose
of 375 mg per square meter weekly for 4 weeks
starting on day 1 of cycle 2 and then on day 1 of
cycles 3 through 6). Patients in the bendamustineplus-rituximab group who had disease progression could cross over to receive ibrutinib within
1 year after progression. Details regarding treatment, including instructions for dose delays and
modifications, are provided in the Methods section in the Supplementary Appendix.
End Points and Assessments

The primary end point was progression-free survival, which was defined as the time from the
date of randomization until the earliest date on
which disease progression (as defined by IWCLL
criteria) or death from any cause was recorded.
Data from patients who were alive and had not
n engl j med 379;26

had disease progression were censored on the date
of the last assessment. Data from patients who
started a therapy for CLL that was not specified
in the protocol or withdrew consent for further
follow-up were also censored on the date of the
last assessment.
A secondary end point was overall survival.
Assessments of response and complete response
were performed by means of computed tomography (CT) and physical examination. A central
assessment of minimal residual disease in bone
marrow was performed at cycle 9 with the use of a
standard flow-based assay, which is capable of
detecting 1 tumor cell in 10,000 cells. An adverse-event analysis was also performed.
For a correlative analysis, patients underwent
a geriatric assessment and central laboratory studies before treatment. The geriatric assessment
included an analysis of the score for activities of
daily living (with scores ranging from 0 to 14 and
higher scores indicating better performance) and
of the number of coexisting conditions. Details
regarding these assessments are provided in the
Supplementary Appendix.
Statistical Analysis

For the comparison of ibrutinib with bendamustine plus rituximab, we estimated that a sample
of 332 patients, with an expected 159 events,
would provide the trial with 90% power to detect
a hazard ratio for disease progression or death of
0.586 (corresponding to an estimated percentage
of patients with progression-free survival at 2 years
of 61% with bendamustine plus rituximab and
75% with ibrutinib), at a one-sided significance
level of 0.025 by a log-rank test. The same assumptions, sample, and power calculation applied for
the comparison of ibrutinib plus rituximab with
bendamustine plus rituximab. If ibrutinib and
ibrutinib plus rituximab were each superior to
bendamustine plus rituximab, then ibrutinib
plus rituximab was to be compared with ibrutinib. For the comparison of ibrutinib plus rituximab with ibrutinib, we estimated that a sample
of 332 patients, with an expected 119 events,
would provide the trial with 90% power to detect
a hazard ratio of 0.57 (corresponding to an estimated percentage of patients with progressionfree survival at 2 years of 75% with ibrutinib and
85% with ibrutinib plus rituximab), at a onesided significance level of 0.05 by a log-rank
test. Thus, the total planned sample was 498

nejm.org

December 27, 2018

2519

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 24, 2019. For personal use only. No other uses without permission.
Copyright © 2018 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

patients who could be evaluated, or 166 patients
per group.
For the comparisons of ibrutinib and ibrutinib
plus rituximab with bendamustine plus rituximab, three interim efficacy and futility analyses
were planned. For the comparison of ibrutinib plus
rituximab with ibrutinib, two interim efficacy
and futility analyses were planned. In May 2018,
the Alliance Data and Safety Monitoring Board
made the decision to release these data on the
basis of the results of the protocol-specified second interim analysis for the comparisons of the
two ibrutinib-containing regimens with bendamustine plus rituximab and the protocol-specified first interim analysis for the comparison of
ibrutinib plus rituximab with ibrutinib.
In accordance with the protocol, the primary
analysis of progression-free survival included all

of

m e dic i n e

patients who underwent randomization except
those who, after randomization, were determined
to have not met the eligibility criteria at screening.
P values for the primary analysis are one-sided.
Secondary analyses included all patients who underwent randomization, regardless of eligibility.
P values for all secondary analyses are two-sided.
Prespecified and exploratory subgroup analyses
were also performed. All analyses were performed
by the Alliance Statistics and Data Center with the
use of SAS software, version 9.4. Data were locked
for this analysis as of October 4, 2018.

R e sult s
Patient Characteristics

From December 2013 to May 2016, a total of 644
patients were preregistered and 547 were enrolled

644 Patients were screened for eligibility

97 Were excluded
52 Did not meet eligibility criteria
19 Were not enrolled owing to investigator decision
16 Were not enrolled owing to patient decision
10 Were not enrolled for other reasons

547 Underwent randomization
(1:1:1)

183 Were assigned to receive
bendamustine+rituximab

182 Were assigned to receive
ibrutinib

182 Were assigned to receive
ibrutinib+rituximab

30 Crossed over from
bendamustine+
rituximab to ibrutinib

176 Were included in primary analysis
7 Did not meet eligibility criteria
and were excluded

178 Were included in primary analysis
4 Did not meet eligibility criteria
and were excluded

170 Were included in primary analysis
12 Did not meet eligibility criteria
and were excluded

176 Were included in adverse-event
analysis
7 Did not begin treatment and
were excluded

180 Were included in adverse-event
analysis
2 Did not begin treatment and
were excluded

181 Were included in adverse-event
analysis
1 Did not begin treatment and
was excluded

183 Were included in secondary
analyses

182 Were included in secondary
analyses

182 Were included in secondary
analyses

Figure 1. Screening, Randomization, and Analysis.
Of the 547 patients who underwent randomization, 23 (4%) were determined to have not met the eligibility criteria
at screening and were excluded from the primary analysis, in accordance with the protocol. These patients were in‑
cluded in the intention-to-treat analysis.
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at 219 sites throughout the United States and
Canada (Fig. 1, and see the Supplementary Appendix). Of the 547 patients who were enrolled in
the trial, 183 were randomly assigned to receive
bendamustine plus rituximab, 182 to receive
ibrutinib, and 182 to receive ibrutinib plus rituximab. The characteristics of the patients were
typical of a population with untreated CLL (Table 1, and Table S2 in the Supplementary Appendix); the median age was 71 years (range, 65 to
89), and 367 patients (67%) were men.
With regard to risk factors for CLL, 46% of the
patients had intermediate-risk disease and 54%
had high-risk disease according to modified Rai
stage, 53% had ZAP70-unmethylated disease on
central testing (with ZAP70-unmethylated disease

status used as a surrogate for IgVH-unmutated
disease status), and 27% had disease associated
with the presence of del(17p13.1) or del(11q22.3)
on local FISH analysis. A separate, central FISH
analysis performed with the use of the hierarchical classification method established by Döhner
et al.20 revealed the presence of del(17p13.1) in
6% of the patients, del(11q22.3) in 19%, trisomy
12 in 22%, and del(13q14.3) in 36%, as well as
the absence of all these abnormalities in 17%. In
addition, 29% of the patients had a complex karyotype, with at least three unrelated cytogenetic abnormalities as assessed by central review,21 and
10% had a mutation in TP53 with a variant allele
frequency of more than 10%. Of the 360 patients
who underwent central sequencing of IgVH genes,

Table 1. Characteristics of the Patients at Baseline.

Characteristic

All Patients
(N = 547)

Bendamustine+
Rituximab
(N = 183)

Ibrutinib
(N = 182)

Ibrutinib+
Rituximab
(N = 182)

71

70

71

71

Age — yr

P Value*
0.53

Median

65–89

65–86

65–89

65–86

Male sex — no. (%)

Range

367 (67)

119 (65)

123 (68)

125 (69)

0.75

High-risk disease according to modified Rai stage
— no. (%)

296 (54)

99 (54)

99 (54)

98 (54)

0.99

ECOG performance-status score — no. (%)†

0.06

0

271 (50)

98 (54)

87 (48)

86 (47)

1

259 (47)

75 (41)

90 (49)

94 (52)

2

17 (3)

10 (5)

5 (3)

2 (1)

FISH analysis according to hierarchical classification
of Döhner et al. — no./total no. (%)‡

0.99

Del(17p13.1)

34/542 (6)

14/181 (8)

9/181 (5)

11/180 (6)

Del(11q22.3)

105/542 (19)

33/181 (18)

35/181 (19)

37/180 (21)

Trisomy 12

118/542 (22)

40/181 (22)

40/181 (22)

38/180 (21)

90/542 (17)

29/181 (16)

32/181 (18)

29/180 (16)

195/542 (36)

65/181 (36)

65/181 (36)

65/180 (36)

51/510 (10)

16/174 (9)

15/168 (9)

20/168 (12)

0.60

Complex karyotype — no./total no. (%)§

143/499 (29)

44/166 (27)

39/165 (24)

60/168 (36)

0.04

Unmethylated ZAP70 — no./total no. (%)

287/546 (53)

95/182 (52)

96/182 (53)

96/182 (53)

0.99

Unmutated IgVH gene — no./total no. (%)¶

218/360 (61)

71/123 (58)

77/122 (63)

70/115 (61)

0.69

None
Del(13q14.3)
Mutated TP53 — no./total no. (%)

*	All P values are for comparisons across all three treatment groups and are two-sided. P values for continuous variables were calculated with
the use of the Kruskal–Wallis test, and P values for categorical variables were calculated with the use of the chi-square test or Fisher’s exact
test.
†	Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability.
‡	Central fluorescence in situ hybridization (FISH) analysis was performed with the use of the hierarchical classification method established
by Döhner et al.20
§	Complex karyotype was defined as the presence of at least three unrelated abnormalities as assessed by central review.
¶	IgVH denotes immunoglobulin variable heavy chain.
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A Primary Analysis
100

Patients Who Were Alive and Free
from Disease Progression (%)

90

Ibrutinib+
rituximab

80
70

Ibrutinib

60
Bendamustine+
rituximab

50
40
30

No. of Events/No. of Patients Median (95% CI)
mo
Bendamustine+Rituximab
68/176
43 (38–NR)
10
34/178
NR
Ibrutinib
32/170
NR
Ibrutinib+Rituximab

20

0

0

6

12

18

24

30

36

42

48

52

88
120
115

57
78
74

26
45
40

11
22
20

0
0
0

Months
No. at Risk
Bendamustine+rituximab 176
Ibrutinib
178
Ibrutinib+rituximab
170

140
165
159

129
154
145

122
147
138

103
136
132

B Subgroup Analysis
No. of No. of
Patients Events

Subgroup
All patients
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib
Risk category according to modified Rai stage
Intermediate
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib
High
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib
Status with regard to del(17p13.1) or del(11q22.3)
Absent
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib
Present
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib
ZAP70 methylation status
Unmethylated
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib
Methylated
Ibrutinib vs. bendamustine+rituximab
Ibrutinib+rituximab vs. bendamustine+rituximab
Ibrutinib+rituximab vs. ibrutinib

Hazard Ratio for Disease Progression
or Death (95% CI)

365
365
364

105
106
69

0.37 (0.25–0.56)
0.40 (0.27–0.60)
1.06 (0.66–1.70)

167
168
167

53
49
32

0.44 (0.25–0.78)
0.32 (0.17–0.59)
0.73 (0.36–1.46)

198
197
197

52
57
37

0.33 (0.18–0.60)
0.50 (0.29–0.85)
1.44 (0.75–2.76)

263
265
266

70
72
52

0.44 (0.27–0.72)
0.50 (0.31–0.80)
1.11 (0.65–1.92)

102
100
98

35
34
17

0.26 (0.12–0.56)
0.24 (0.11–0.53)
0.90 (0.35–2.32)

191
191
192

61
68
35

0.19 (0.11–0.35)
0.31 (0.18–0.51)
1.57 (0.80–3.09)

173
173
172

43
37
34

0.81 (0.45–1.48)
0.58 (0.30–1.12)
0.72 (0.36–1.43)

0.0625 0.1250 0.2500 0.5000 1.000 2.000 4.000

Better
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Figure 2 (facing page). Primary and Subgroup Analyses
of Progression-free Survival.
Panel A shows Kaplan–Meier estimates of progres‑
sion-free survival for each treatment group. The pri‑
mary analysis included all patients who underwent
randomization and were determined to have met the
eligibility criteria at screening. Panel B shows hazard
ratios for disease progression or death at the time of
data cutoff, according to subgroups that were based
on risk factors for chronic lymphocytic leukemia. The
subgroup analysis was performed in the intention-totreat population. Hazard ratios were calculated with
univariable Cox proportional-hazards models. NR de‑
notes not reached.

61% had IgVH-unmutated disease. There was no
significant difference among the three treatment
groups with regard to baseline characteristics,
with the exception of a higher percentage of patients with a complex karyotype in the ibrutinibplus-rituximab group than in the other two treatment groups (P = 0.04).
Of the 524 patients who were enrolled in the
trial and were determined to have met the eligibility criteria at screening, 389 patients (74%) consented to undergo the geriatric assessment for the
correlative analysis, and 369 of those patients
(95%) completed the assessment before treatment.
The mean (±SD) score for activities of daily living
was 13.7±0.8 (range, 9 to 14), and the mean number of coexisting conditions was 2.5±1.9 (range,
0 to 14) (Table S3 in the Supplementary Appendix). There was no significant difference among
the three treatment groups with regard to results
on the geriatric assessment.
Progression-free Survival and Overall
Survival

Of the 547 patients who underwent randomization, 524 (96%) were determined to have met the
eligibility criteria at screening and were included
in the primary analysis. Median progression-free
survival was reached only with bendamustine plus
rituximab. The estimated percentage of patients
with progression-free survival at 2 years was 74%
(95% confidence interval [CI], 66 to 80) with
bendamustine plus rituximab, as compared with
87% (95% CI, 81 to 92) with ibrutinib and 88%
(95% CI, 81 to 92) with ibrutinib plus rituximab
(Fig. 2A). The hazard ratio for disease progression or death was 0.39 (95% CI, 0.26 to 0.58) for
the comparison of ibrutinib with bendamustine
plus rituximab (one-sided P<0.001) and 0.38
n engl j med 379;26

(95% CI, 0.25 to 0.59) for the comparison of ibrutinib plus rituximab with bendamustine plus
rituximab (one-sided P<0.001). There was no significant difference between the ibrutinib-plusrituximab group and the ibrutinib group with
regard to progression-free survival (hazard ratio,
1.00; 95% CI, 0.62 to 1.62; one-sided P = 0.49)
(Fig. 2A). In an intention-to-treat analysis, which
included all patients who underwent randomization, the same conclusions were reached (Fig. S1
in the Supplementary Appendix).
In analyses of subgroups that were defined according to risk factors for CLL, progression-free
survival was longer with the ibrutinib-containing
regimens than with bendamustine plus rituximab
in all risk factor–related subgroups, but the difference was not significant among patients with
ZAP70-methylated disease (Fig. 2B). In exploratory
analyses of subgroups that were defined according to cytogenetic factors, there was an interaction between cytogenetics and the effect of treatment on progression-free survival. Progression-free
survival was longer with the ibrutinib-containing
regimens than with bendamustine plus rituximab
in all cytogenetic factor–related subgroups, but
the difference was greater among patients with
del(17p13.1) (Fig. S2 in the Supplementary Appendix). In an additional analysis, progression-free
survival was longer among patients with IgVHmutated disease than among those with IgVHunmutated disease (hazard ratio, 0.51; 95% CI,
0.32 to 0.81), but there was no significant interaction between IgVH mutation status and the effect of treatment on progression-free survival. Details regarding this analysis are provided in Tables
S4 and S5 and Figure S3 in the Supplementary
Appendix.
At the time of data cutoff, 66 deaths had occurred. The estimated percentage of patients with
overall survival at 2 years was 95% (95% CI, 91
to 98) with bendamustine plus rituximab, 90%
(95% CI, 85 to 94) with ibrutinib, and 94%
(95% CI, 89 to 97) with ibrutinib plus rituximab.
There was no significant difference among the
three treatment groups with regard to overall survival (P≥0.65 for all pairwise comparisons) (Fig. S4
in the Supplementary Appendix).
Treatment and Response

At the time of data cutoff, the median follow-up
was 38 months among the 481 patients who were
alive. A total of 114 of 182 patients (63%) in the
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ibrutinib group and 117 of 182 patients (64%) in
the ibrutinib-plus-rituximab group were still receiving ibrutinib, and 88 of 183 patients (48%)
in the bendamustine-plus-rituximab group were
still in remission and undergoing surveillance in
the trial after completion of treatment. In the
bendamustine-plus-rituximab group, 67% of the
patients received six cycles of treatment; the number of cycles received ranged from one to six,
with a dose held in 67% of the patients and the
dose reduced in 37%. In the ibrutinib group,
the median duration of treatment at the time of
data cutoff was 32 months (range, 0 to 51), with
the dose reduced in 13% of the patients. In the
ibrutinib-plus-rituximab group, the median duration of ibrutinib treatment at the time of data
cutoff was 32 months (range, 0 to 52), with the
dose reduced in 14% of the patients; 92% of the
patients received all planned doses of rituximab.
The best response was determined by means
of CT and physical examination in 504 patients
(92%) and by means of physical examination alone
in 18 (3%) and was not evaluated in 25 (5%).
Among all the patients, the response rate was
lower with bendamustine plus rituximab than
with the ibrutinib-containing regimens: 81%
(95% CI, 75 to 87) with bendamustine plus rituximab, as compared with 93% (95% CI, 88 to 96)
with ibrutinib and 94% (95% CI, 89 to 97) with
ibrutinib plus rituximab. However, the complete
response rate was higher with bendamustine plus
rituximab than with the ibrutinib-containing regimens: 26% (95% CI, 20 to 33), as compared with
7% (95% CI, 4 to 12) and 12% (95% CI, 8 to 18).
The percentage of patients with undetectable
minimal residual disease was significantly higher
with bendamustine plus rituximab than with the
ibrutinib-containing regimens: 8% (95% CI, 5 to
13), as compared with 1% (95% CI, <1 to 3) and
4% (95% CI, 2 to 8).

of

m e dic i n e

ibrutinib plus rituximab (41% and 39%, respectively), whereas the rate of grade 3, 4, or 5 nonhematologic adverse events was lower with
bendamustine plus rituximab (63%) than with the
ibrutinib-containing regimens (74% with each
regimen). Infections occurred in all three treatment groups, with respiratory tract infections,
urinary tract infections, sepsis, and abdominal
infections being the most common (Table 3, and
Table S6 in the Supplementary Appendix). Atrial
fibrillation of any grade occurred in 3% of the
patients in the bendamustine-plus-rituximab
group, 17% in the ibrutinib group, and 14% in the
ibrutinib-plus-rituximab group. Grade 3 or higher
hypertension occurred in 14%, 29%, and 34%,
respectively. Summaries of all adverse events are
provided in Tables S7 through S10 in the Supplementary Appendix.
Death occurred during treatment or within
30 days after treatment discontinuation in 2 patients (1%) in the bendamustine-plus-rituximab
group, 13 (7%) in the ibrutinib group, and 13 (7%)
in the ibrutinib-plus-rituximab group. Death occurred within the first six cycles of treatment,
within 30 days after the sixth cycle among those
who completed six cycles, or within 30 days after
treatment discontinuation among those who did
not complete six cycles in 2 patients (1%) in the
bendamustine-plus-rituximab group, 3 (2%) in the
ibrutinib group, and 6 (3%) in the ibrutinib-plusrituximab group. All causes of death are shown in
Table S11 in the Supplementary Appendix.
Secondary cancers occurred in 13% of the patients in the bendamustine-plus-rituximab group
(excluding events that occurred after crossover),
13% in the ibrutinib group, and 16% in the ibrutinib-plus-rituximab group. Richter’s transformation
(CLL that evolved into an aggressive lymphoma)
occurred in 1 patient in the bendamustine-plusrituximab group and in 2 patients in the ibrutinibplus-rituximab group.

Adverse Events

Because adverse events associated with these
treatments have been reported extensively in the
literature, we have focused on grade 3 or higher
adverse events of special interest (Table 2). These
adverse events are reported regardless of attribution and include events that occurred during treatment and follow-up, excluding events that occurred
after crossover. The rate of grade 3, 4, or 5 hematologic adverse events was higher with bendamustine plus rituximab (61%) than with ibrutinib or
2524
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Discussion
In this phase 3 trial, we found that treatment with
continuous ibrutinib, either alone or in combination with rituximab, was superior to treatment
with six cycles of bendamustine plus rituximab
with regard to progression-free survival. We also
found that there was no significant difference
between ibrutinib and ibrutinib plus rituximab
with regard to progression-free survival. An on-

nejm.org

December 27, 2018

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 24, 2019. For personal use only. No other uses without permission.
Copyright © 2018 Massachusetts Medical Society. All rights reserved.

Ibrutinib Regimens vs. Chemoimmunother apy in CLL

Table 2. Summary of Grade 3, 4, or 5 Adverse Events.*
Bendamustine+
Rituximab
(N = 176)

Adverse Event

Ibrutinib
(N = 180)

Ibrutinib+
Rituximab
(N = 181)

P Value†

number of patients (percent)
Hematologic
Any
Grade 3
Grade 4
Anemia
Grade 3
Grade 4
Decreased neutrophil count
Grade 3
Grade 4
Decreased platelet count
Grade 3
Grade 4
Nonhematologic
Any
Grade 3
Grade 4
Grade 5
Bleeding‡
Grade 3
Grade 4
Grade 5
Infection§
Grade 3
Grade 4
Grade 5
Febrile neutropenia
Grade 3
Atrial fibrillation
Grade 3
Grade 4
Hypertension
Grade 3
Grade 4
Secondary cancer
Grade 3
Grade 4
Grade 5
Unexplained or unwitnessed death
Grade 5

<0.001
62 (35)
45 (26)

59 (33)
15 (8)

49 (27)
21 (12)

22 (12)
0

20 (11)
1 (1)

11 (6)
0

39 (22)
32 (18)

15 (8)
12 (7)

20 (11)
19 (10)

16 (9)
10 (6)

9 (5)
3 (2)

8 (4)
1 (1)

76 (43)
20 (11)
15 (9)

97 (54)
12 (7)
24 (13)

100 (55)
12 (7)
22 (12)

0
0
0

2 (1)
1 (1)
0

3 (2)
1 (1)
1 (1)

17 (10)
6 (3)
3 (2)

29 (16)
6 (3)
2 (1)

28 (15)
7 (4)
2 (1)

13 (7)

3 (2)

1 (1)

5 (3)
0

15 (8)
2 (1)

10 (6)
0

24 (14)
1 (1)

53 (29)
0

60 (33)
1 (1)

6 (3)
0
1 (1)

5 (3)
1 (1)
4 (2)

13 (7)
1 (1)
1 (1)

2 (1)

7 (4)

4 (2)

0.09

<0.001

0.008

0.04

0.46

0.62

<0.001
0.05

<0.001

0.17

0.24

*	Shown are adverse events that occurred during treatment or follow-up, excluding events that occurred after crossover.
The adverse-event analysis included all patients who began the assigned treatment.
†	All P values are for comparisons across all three treatment groups and are two-sided. P values were calculated with the
use of Fisher’s exact test.
‡	Bleeding events included epistaxis (in three patients), epistaxis and oral hemorrhage (in one patient), and intracranial
hemorrhage (in four patients, including one with a grade 5 event).
§	Details regarding infections are provided in Table 3.
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Table 3. Summary of Grade 3, 4, or 5 Infections.*
Bendamustine+
Rituximab
(N = 176)

Type of Infection

Ibrutinib
(N = 180)

Ibrutinib+
Rituximab
(N = 181)

number of patients (percent)
Abdominal infection: appendicitis or enterocolitis
Grade 3

0

2 (1)

2 (1)

8 (5)

14 (8)

15 (8)

Grade 3

14 (8)

11 (6)

17 (9)

Grade 5

0

1 (1)

0

Grade 3

0

1 (1)

1 (1)

Grade 4

0

1 (1)

0

Grade 5

1 (1)

0

0

Grade 4

6 (3)

5 (3)

7 (4)

Grade 5

2 (1)

1 (1)

2 (1)

3 (2)

4 (2)

5 (3)

Other infection or infestation: conjunctivitis, hepatitis
virus infection, otitis media, or infection in‑
volving the bone, joint, lymph gland, scrotum,
tooth, skin, or a wound
Grade 3
Respiratory tract infection: bronchial, lung, or upper
respiratory infection

Central nervous system infection: encephalitis
or meningitis

Sepsis

Urinary tract infection, including bladder infection
Grade 3

*	Shown are infections that occurred during treatment or follow-up, excluding events that occurred after crossover.

going National Clinical Trials Network (NCTN)
trial (ClinicalTrials.gov number, NCT02048813)
aims to evaluate whether treatment with ibrutinib
plus rituximab is superior to chemoimmunotherapy
among younger adults.
Improvement in overall survival is the ultimate
goal of new therapies, and in this analysis, there
was no significant difference among the three
treatment groups with regard to overall survival,
although the follow-up period was short for this
disease. The rate of grade 5 adverse events was
higher than expected with the ibrutinib-containing regimens, although this finding may be due
to the crossover design and relatively short followup. At the time of this analysis, the most common
causes of death associated with the ibrutinib-containing regimens, aside from CLL, included unexplained or unwitnessed death, infection, and
secondary cancers. It is not clear that these events
occur more frequently with ibrutinib than with
2526
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bendamustine plus rituximab, but they will be
monitored closely in long-term follow-up. Both
atrial and ventricular arrhythmias are known complications of ibrutinib treatment22,23 that have potentially devastating consequences. The mechanism that underlies this association remains
unclear but may be related to alternative targets
of ibrutinib, since the incidence of these events
is lower with the use of more specific BTK inhibitors.24,25 The patients who are at highest risk
for these events and viable treatment options for
those patients have not yet been identified.
Although this trial was not powered to detect
differences among subgroups, the results of our
subgroup analyses raise a few points. First, treatment with the ibrutinib-containing regimens, with
ibrutinib administered continuously until disease
progression, appeared to result in longer progression-free survival than treatment with six cycles
of bendamustine plus rituximab in all cytogenetic
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factor–related subgroups, as well as among patients with IgVH-mutated and IgVH-unmutated
disease. In addition, the presence of a complex
karyotype, which has previously been shown to
be an indicator of poor prognosis, did not appear
to influence ibrutinib-induced progression-free
survival. Most data regarding complex karyotype
are from patients with relapsed CLL, so it is possible that the presence of a complex karyotype is
biologically different in the absence of DNA-damaging therapy. During long-term follow-up, further study of complex karyotype in these patients
is warranted.
The results of this analysis show the efficacy
of treatment with continuous ibrutinib among
patients with untreated CLL, but the results also
raise the issue of whether indefinite therapy with
a BTK inhibitor is needed. The significantly lower
rates of undetectable minimal residual disease
with the ibrutinib-containing regimens than with
bendamustine plus rituximab suggest that treatment with single-agent ibrutinib must be continued indefinitely. Treatments with combined targeted therapies, with the goal of increasing the

rate of undetectable minimal residual disease and
ultimately discontinuing treatment, have shown
promise in early clinical studies26,27 and will be
evaluated in upcoming NCTN studies (NCT03737981
and NCT03701282), which may help to address
this issue.
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